Back to results
US 2012/0058182 A9Published application
Method and composition for administering an nmda receptor antagonist to a subject
AssigneeAdamas Pharmaceuticals, Inc.
InventorsGregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
Claims2
1-58. (canceled)
A method of achieving a therapeutically effective steady state memantine plasma concentration in less than 20 days of initiation of memantine therapy in a patient that comprises administering an extended release coated pellet capsule formulation of 10-100 mg memantine.
Dependencies are inferred from the claim text.